购物车
- 全部删除
- 您的购物车当前为空
Ryuvidine 是一种 KDM5A 和 SETD8 双重抑制剂,是一种 DNA 损伤反应的诱导剂,具有潜在的抗癌活性,抑制 H4K20 甲基化,抑制 CDK4,可用于研究乳腺癌和红斑病。
为众多的药物研发团队赋能,
让新药发现更简单!
Ryuvidine 是一种 KDM5A 和 SETD8 双重抑制剂,是一种 DNA 损伤反应的诱导剂,具有潜在的抗癌活性,抑制 H4K20 甲基化,抑制 CDK4,可用于研究乳腺癌和红斑病。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 573 | 现货 | |
5 mg | ¥ 1,390 | 现货 | |
10 mg | ¥ 1,980 | 现货 | |
25 mg | ¥ 3,530 | 现货 | |
50 mg | ¥ 4,930 | 现货 | |
100 mg | ¥ 6,960 | 现货 | |
500 mg | ¥ 13,900 | 现货 |
产品描述 | Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response with potential anticancer activity, inhibition of H4K20 methylation, and inhibition of CDK4, and can be used to study breast cancer and erythroplasia. |
靶点活性 | CDK4:6.0 μM |
分子量 | 284.33 |
分子式 | C15H12N2O2S |
CAS No. | 265312-55-8 |
Smiles | Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |
密度 | 1.416g/cm3 |
存储 | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||
溶解度信息 | DMF: 2 mg/mL (2.65 mM), Sonication is recommended. DMSO: 1 mg/mL (3.52 mM), Sonication is recommended. | ||||||||||
溶液配制表 | |||||||||||
DMF/DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容